🇺🇸 FDA
Company

Medicenna

Medicenna Therapeutics

MDNAF pharma USA

Quick answer

Medicenna is a pharma company (MDNAF) headquartered in TORONTO, A6, USA with 2 tracked pipeline programs.

Pipeline (2)

project

MDNA11

Advanced Solid Tumor

Phase 2 · small_molecule · active

1 trials project

MDNA55

Glioblastoma

Phase 2 · small_molecule · completed

1 trials

Patents (8)

patent

US 12404497

Uses and methods for oncolytic virus targeting of IL-4/IL-13 and fusions thereof

Expires Mon Aug 28 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12338269

IL-2 superagonists in combination with anti-PD-1 antibodies

Expires Mon Jun 19 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 12274735

IL-4-fusion formulations for treatment of central nervous system (CNS) tumors

Expires Mon Apr 10 2045 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11680090

Interleukin-2 fusion proteins and uses thereof

Expires Mon Jun 15 2043 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11542312

IL-2 superagonists in combination with anti-PD-1 antibodies

Expires Mon Dec 29 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 11352402

Interleukin-4 receptor-binding fusion proteins and uses thereof

Expires Mon Jun 02 2042 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10781242

Interleukin-2 fusion proteins and uses thereof

Expires Mon Sep 17 2040 00:00:00 GMT+0000 (Coordinated Universal Time)

 patent

US 10106592

Interleukin-4 receptor-binding fusion proteins and uses thereof

Expires Mon Oct 18 2038 00:00:00 GMT+0000 (Coordinated Universal Time)